133 related articles for article (PubMed ID: 10423661)
1. Advances in cardiovascular pharmacology: protocol design and methodology--the US regulatory process.
Somberg JC; Borer JS
Am J Ther; 1999 May; 6(3):175-8. PubMed ID: 10423661
[No Abstract] [Full Text] [Related]
2. Between a rock and a hard place.
Demaria AN
J Am Coll Cardiol; 2010 Nov; 56(21):1761-2. PubMed ID: 21070930
[No Abstract] [Full Text] [Related]
3. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
Binzak BA
Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
[No Abstract] [Full Text] [Related]
4. Protocol design.
Wilensky AJ
Epilepsy Res Suppl; 1993; 10():107-13. PubMed ID: 8251086
[No Abstract] [Full Text] [Related]
5. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
Roden DM; Temple R
Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869
[No Abstract] [Full Text] [Related]
6. Science and regulatory rituals associated with the drug development process.
Versteegh LR
Food Drug Law J; 1997; 52(2):155-61. PubMed ID: 10557552
[No Abstract] [Full Text] [Related]
7. The process of drug development.
Burgess G
Surviv News (Atlanta Ga); 2002 Mar; ():18. PubMed ID: 11966191
[No Abstract] [Full Text] [Related]
8. The domestic drug regulatory process: why time is of the essence.
Katz R
Epilepsy Res Suppl; 1993; 10():91-106. PubMed ID: 8251109
[No Abstract] [Full Text] [Related]
9. The United States Food and Drug Administration and the end of antibiotics.
Shlaes DM; Moellering RC
Clin Infect Dis; 2002 Feb; 34(3):420-2. PubMed ID: 11774094
[No Abstract] [Full Text] [Related]
10. Drug development process for a product with a primary pediatric indication.
Allen AJ; Michelson D
J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
[TBL] [Abstract][Full Text] [Related]
11. The FDA's drug review process: ensuring drugs are safe and effective.
Meadows M
FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
[No Abstract] [Full Text] [Related]
12. US court rules to allow experimental drugs for dying patients.
Waltz E
Nat Med; 2006 Jun; 12(6):596. PubMed ID: 16760988
[No Abstract] [Full Text] [Related]
13. New clinical trials policy at FDA.
Vastag B
Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
[No Abstract] [Full Text] [Related]
14. The problem of new uses.
Eisenberg RS
Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
[No Abstract] [Full Text] [Related]
15. Drive for drugs leads to baby clinical trials.
Nature; 2006 Mar; 440(7083):406-7. PubMed ID: 16554774
[No Abstract] [Full Text] [Related]
16. Cancer drug approval in the United States, Europe, and Japan.
Milsted RA
Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
[No Abstract] [Full Text] [Related]
17. To market, to market. The nuts and bolts of prescription drug approval.
Peterson AM
Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443
[No Abstract] [Full Text] [Related]
18. On approval.
Huff B
GMHC Treat Issues; 2001 Oct; 15(10):5-8. PubMed ID: 11727570
[No Abstract] [Full Text] [Related]
19. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
20. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
